Important Note: Redirection of Services to ChiCTR
We would like to inform you that the Clinical Trial Registry page will discontinue the function of updating trial information directly on this platform. However, you will still be able to view the existing registration details. For any updates to trial information, you can use the China Clinical Trial Registry (ChiCTR) directly at https://www.chictr.org.cn. This change will be fully implemented by 2024-Aug-05. Thank you for your attention.
CUHK_CCT00163
2008-04-22
Prospective
Nil
Nil
Division of Urology, Department of Surgery, The Chinese University of Hong Kong
NA
Ng Chi Fai
Department of Surgery, 4/F, Clinical Science Building, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, NT
Phone: 26322625, Fax: 26377974,
e-mail: ngcf@surgery.cuhk.edu.hk
Professor, Department of Surgery
Ng Chi Fai
Department of Surgery, 4/F, Clinical Science Building, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, NT
Phone: 26322625, Fax: 26377974,
e-mail: ngcf@surgery.cuhk.edu.hk
Professor, Department of Surgery
Effect of Shi Wei on urine biochemistry and crystallization properties in renal stone formers
Effect of Shi Wei on urine biochemistry and crystallization properties in renal stone formers
Nil
Hong Kong
Yes
2007-10-04
Renal stone
Drug
Shi Wei
7 days
Placebo
Inclusion criteria 1.Male patients (age 30-70 years, body weight 55-80 kg) either have recurrent stone disease or new stone former. 2.They are idiopathic stone-formers (includes calcium oxalate, calcium phosphate & uric acid) that is, without underlying urological anomalies such as, medullar sponge kidney, gastrointestinal disorders, hyperparathyroidism or other hypercalcemic disorders, sarcoidosis, Paget's disease, renal tubular acidosis, primary hyperoxaluria, gout or other hyperuricemic disorders, or drugs inducing nephrolithiasis.
Exclusion criteria 1.Patient with active urinary infection, obstruction or hematuria during the study period 2.change of any medication for other medical diseases during the study period 3.Abnormal renal function (Serum creatinine levels that are more than 1.5 times upper limit of normal range, UML.) 4.abnormal liver function (ALT > 1.5 x UNL associated with alkaline phosphatase > 2.5 x UNL are not eligible for the study)
>=18
nil
Both Male and Female
Interventional
Randomized
Placebo
Double-blind
Parallel
2008-05-02
100
Complete
The effects of Shi Wei on the biochemistry of early morning urine in idiopathic calcium renal stone formers.
The effects of Shi Wei on quantity, size and aggregation of stone crystals in vivo by image analysis.
2009-11-20
ChiCTR-TRC-09000720
2010-05-04
Yes
nil
|
|
|
|
|
---|---|---|---|---|
No documents yet. |